Search
Donislecel
go.drugbank.com/drugs/DB17961Approved[L47196] Overall, 21 patients achieved insulin independence for a year or more, with 11 patients not needing insulin for 1 to 5 years and 10 patients for more than 5 years. … [L47166,L47196] The approval of donislecel was based on the safety and effectiveness evaluated in 2 clinical trials with 30 type 1 diabetic patients.
Categories: Drugs Used in DiabetesRabeprazole
go.drugbank.com/drugs/DB01129ApprovedInvestigationalRabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. … Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
Mixtures: RASOFORCE 20/1680 MG TOZ İÇEREN SAŞE, 14 SAŞE, RASOFORCE 20/1680 MG TOZ İÇEREN SAŞE, 28 SAŞECategories: Antiinflammatory Preparations, Non-Steroids for Topical Use, Drugs for Acid Related DisordersBerahyaluronidase alfa
go.drugbank.com/drugs/DB22790ApprovedInvestigationalThis combination was approved by the US FDA in September 2025 and is indicated for various solid tumors in adults and pediatric patients 12 years and older, offering a subcutaneous option for indications … It is used in a fixed-dose combination with [pembrolizumab] for subcutaneous injection.
Dolutegravir
go.drugbank.com/drugs/DB08930ApprovedInvestigational[L1035] On November 21, 2017, dolutegravir, in combination with rilpivirine, was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named … [A7514] The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity.
Categories: Antivirals used in combination for the treatment of HIV infections, Antivirals for Systemic UseIvosidenib
go.drugbank.com/drugs/DB14568ApprovedInvestigational[L48781] In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of ivosidenib and recommended it be granted marketing authorization for the treatment … [A248745] It is currently approved to also treat newly diagnosed acute myeloid leukemia in older adults in combination [azacitidine] or as monotherapy, as well as locally advanced or metastatic cholangiocarcinoma
Aminosalicylic acid
go.drugbank.com/drugs/DB00233ApprovedInvestigationalAn antitubercular agent often administered in association with isoniazid. The sodium salt of the drug is better tolerated than the free acid.
Categories: Antiinfectives for Systemic Use, Drugs for Treatment of TuberculosisGlecaprevir
go.drugbank.com/drugs/DB13879ApprovedInvestigationalAs of June 2025, the FDA approved an expanded indication for Mavyret, making it the first and only direct-acting antiviral therapy approved for the treatment of both acute and chronic HCV in patients aged … Mavyret is also indicated for HCV genotype 1-infected patients who have been previously treated with regimens either containing an NS5A inhibitor or an NS3/4A protease inhibitor, but not both [L940].
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseMequinol
go.drugbank.com/drugs/DB09516ApprovedWithdrawnIt is found as an active ingredient in topical drugs used for skin depigmentation indicated for the treatment of solar lentigines. … It is used as an inhibitor for acrylic monomers and acrylonitirles, as a stabilizer for chlorinated hydrocarbons and ethyl cellulose, as an ultraviolet inhibitor, as a chemical intermediate in the manufacture
Categories: Compounds used in a research, industrial, or household settingEtripamil
go.drugbank.com/drugs/DB12605ApprovedInvestigational) to sinus rhythm in adults. … [A275243, A275248] The nasal formulation of etripamil was first approved by the FDA on December 12, 2025 for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT
Streptococcus pneumoniae type 1 capsular polysaccharide antigen
go.drugbank.com/drugs/DB10319ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 1 capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 1 of *Streptococcus pneumoniae*.
Mixtures: PNEUMOVAX 23 Injektionslösung in einer Fertigspritze, PNEUMOVAX 23 Injektionslösung in einer Durchstechflasche